Macular Degeneration
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Macular Degeneration is a moderately active landscape with 55 programs across 21 companies. The most active players are Daiichi Sankyo, EyePoint Pharmaceuticals, Inc., Quark Pharmaceuticals. 4 therapies are approved with 13 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
78%
Small molecule
46 of 59 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 59 classified programs, each share of the total. Modality classified for 100% of 63 pipeline programs.
Analysis
Trial Status
72
clinical trials
Clinical Trials
Trial Activity
72 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)